Date & Time :  13 October 2026 | 16:30–18:00 CEST | Online

 

 

 

A multidisciplinary webinar exploring the combination of radiotherapy (RT) and immunotherapy in non-small cell lung cancer (NSCLC), examining biological mechanisms, optimal combination strategies, dose/volume/timing considerations, and advanced RT techniques to mitigate immunosuppressive effects.

 

Chairs

• Corinne Faivre-Finn, University of Manchester & The Christie NHS Foundation, Manchester, UK
• Valeria Dionisi, MD, Radiation Oncologist, University Hospital and Trust, Verona, Italy

 

Speakers

• Eleanor Cheadle, University of Manchester (Division of Cancer Sciences), Manchester, UK
• Kersti Oselin,North Estonia Medical Centre, Tallin, EE
• Sara Ramella,Fondazione Policlinico Universitario Campus Bio-Medico, Rome, IT
• Zeno Gouw, Netherlands Cancer Institute, Amsterdam, NL
• Francois de Kermenguy,Harvard Medical School, Boston, US

 

Programme

• 16:30– 16:35 | Introduction by Chairs
• 16:35 – 16:50 | Talk 1 (15 min) — Biologist point of view: A double edge sword: the immunostimulatory and immunosuppressive effect of RT | Eleanor Cheadle
• 16:50 – 17:05 | Talk 2 (15 min) — Medical oncologist point of view: How to best combine Immunotherapy and RT: just a question of timing? | Kersti Oselin
• 17:05 – 17:20 | Talk 3 (15 min) — Radiation oncologist point of view: Early and LA NSCLC: type, dose, volume: what matters the most? | Sara Ramella
• 17:20 – 17:35 | Talk 4 (15 min) — Radiation oncologist point of view: Metastatic NSCLC: do time, dose, volume and type matter? | Zeno Gouw
• 17:35 – 17:50 | Talk 5 (15 min) — Physicist point of view: How to mitigate the immunosuppressive effect of RT with advanced RT techniques? | Francois de Kermenguy
• 17:50 – 18:00 | Open discussion & Closing Remarks

 

Learning Objectives

By the end of this webinar, participants should be able to:

• Understand the biological rationale for combining radiotherapy and immunotherapy in lung cancer.
• Recognise the mechanisms and clinical impact of radiotherapy-induced immunosuppression.
• Identify strategies to overcome immunosuppressive effects, including optimisation of dose, fractionation, and sequencing.
• Discuss key ongoing and future trials evaluating radiotherapy–immunotherapy combinations.
• Apply emerging evidence to inform clinical decision-making and trial development.